Although there are a full range of tools available to countries who wish to increase access to healthcare, compulsory licensing has been described by some as the preferential tool for access.  Increasingly countries are looking to compulsory licensing as a tool to gain access to medicines where no public health emergency or similar circumstances exist.  A panel of experts will look at various approaches and considerations related to increasing access to medicines, including compulsory licensing.  The panel will also look at the economic, investment and access consequences of using compulsory licenses, including countries that have and have not made use of this option as examples.

Ability Level: All

Session ID: 2112

myBIO Chatter

Speakers (4)

contact_9932 Scott Burwell Partner Finnegan, Henderson, Farabow, Garrett & Dunner, LL
contact_2177 Manisha A. Desai, Ph.D. Assistant General Patent Counsel Eli Lilly and Company
contact_8659 David Torstensson Partner Pugatch Consilium
User Durhane Wong-Rieger, PhD Chair, International Alliance of Patients' Organizations Consumer Advocare Network

Moderators (1)

contact_7083 Mark Elliot Executive Vice President U.S. Chamber of Commerce, Global IP Center